Compare Crispr Therapeutics AG (CRSP) vs SOLAI Limited (SLAI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs SOLAI Limited — how do they compare? Crispr Therapeutics AG trades at $54.26 (market cap $5.23B), while SOLAI Limited trades at $3.72 (market cap $16.69M). The key difference: Crispr Therapeutics AG is far larger — about 313.4× SOLAI Limited's market cap, and Crispr Therapeutics AG is trading nearer its 52-week high, SOLAI Limited nearer its low. Which is the better fit depends on your goals.
| CRSP | SLAI | |
|---|---|---|
Market Cap | $5.23B | $16.69M |
Sector | Health | Technology |
52-Week High | $76.78 | $26.74 |
52-Week Low | $44.34 | $2.74 |
Enterprise Value | $3.65B | $16.33M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.83, up 0.6% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a Q2 2026 EPS beat with a loss of $0.94 versus an expected $1.19 loss, driven by surging CASGEVY sales. However, financials show deep losses, with a net income margin of -4,101.26% in 2025 and negative operating cash flow, though financing activities provided liquidity.
The outlook is mixed: strong analyst consensus (57.9% buy ratings) and a $82.67 price target reflect optimism around CASGEVY growth and pipeline catalysts, but high valuation (P/S of 466.05) and persistent cash burn pose significant risks. Investment appeal hinges on successful clinical advancements and path to profitability.
SLAI trades at $3.72 with no recent price change. The stock shows a bullish technical signal, but the company faces severe financial distress with negative gross and net income margins, and a net loss of $33.88 million in 2025. A reverse stock split was executed on July 6, 2026, and the NYSE has commenced delisting proceedings, creating significant uncertainty.
The outlook is highly speculative. The acquisition of a stake in NEURALAND and the launch of Solode Neo represent potential growth avenues, but the delisting risk and persistent losses overshadow any near-term upside. Investors face substantial risk of capital loss.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About SOLAI Limited
SOLAI focuses on providing innovative AI-driven software solutions. The company leverages artificial intelligence to enhance digital experiences and optimize business processes for various industries.
Read more on SLAI →
